# Wisconsin NCI Community Oncology Research Program (WiNCORP)

> **NIH NIH UG1** · MARSHFIELD CLINIC, INC. · 2022 · $2,873,002

## Abstract

PROJECT SUMMARY
The Wisconsin NCORP (WiNCORP) is a consortium of three established healthcare systems in the state of Wisconsin with
a long-standing history of excellence in oncology care – Marshfield Clinic Health System, Gundersen Health System, and
ThedaCare. Through a network of hospitals, clinics, and other facilities spanning most of the state of Wisconsin, upper
Michigan and adjacent counties in Northern Iowa and Southeastern Minnesota, WiNCORP institutions collectively
provide care and access to oncology clinical trials to a predominantly rural population. Member sites participate in
numerous NCI-sponsored clinical trials and are active in NCORP research base committees, NCI task forces and steering
committees, research networks, and organizations with a focus on improving cancer care. Investigators from each
system are consistently recognized by the NCI and/or the research bases for their accrual totals, and WiNCORP has been
designated as a high-performing site over the previous grant cycle. Through the work of multidisciplinary care teams and
research staff, WiNCORP will continue to leverage its collective expertise to open numerous cancer care delivery
research (CCDR) trials. With a shared mission to provide patient access to NCI-sponsored clinical trials, WiNCORP
members are well-positioned to increase patient accruals from historically underrepresented populations in clinical trials
such as rural, elderly, and low-income individuals, enhance cancer care delivery, and reduce disparities in cancer burden
across the region. To achieve this goal, WiNCORP leadership has outlined four specific aims for the consortium: 1)
Conduct NCI Phase I/II, II and III cancer screening, prevention, symptom management, treatment, post-treatment,
imaging and quality of life trials across the entire WiNCORP service area. 2) Facilitate conduct of Cancer Care Delivery
Research (CCDR) across our integrated health care systems through establishment of an expanded research
infrastructure. 3) Facilitate accrual to molecular target driven trials. 4) Incorporate a new patient population and
provider group in the WiNCORP consortium that currently has no access to CCDR studies. These specific aims will be
accomplished by expanding communication channels between patients and WiNCORP members, streamlining the
process of site opening for various clinical trials, enhancing resource sharing among member sites, enhancing
community engagement in clinical trial participation, and continual enhancements and developments in infrastructure
and personnel to open and accrue patients to a variety of clinical trial types. It is anticipated that WiNCORP-wide efforts
in staff education, clinical trial feasibility assessment, harmonized internal processes, synchronized regulatory support,
development of system and trial-specific standard operating procedures, and collaboration among investigators from
the three consortium sites will create a synergy that will further enhance clinical...

## Key facts

- **NIH application ID:** 10451698
- **Project number:** 5UG1CA189956-09
- **Recipient organization:** MARSHFIELD CLINIC, INC.
- **Principal Investigator:** ADEDAYO A ONITILO
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,873,002
- **Award type:** 5
- **Project period:** 2014-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10451698

## Citation

> US National Institutes of Health, RePORTER application 10451698, Wisconsin NCI Community Oncology Research Program (WiNCORP) (5UG1CA189956-09). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10451698. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*